SpringWorks Therapeutics (SWTX) to Release Quarterly Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is projected to announce its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $60.53 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

SpringWorks Therapeutics Stock Down 2.0 %

Shares of NASDAQ:SWTX opened at $57.43 on Tuesday. The business has a fifty day simple moving average of $39.35 and a 200-day simple moving average of $36.86. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $60.00.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $41.97, for a total value of $839,400.00. Following the completion of the sale, the chief operating officer now owns 209,600 shares of the company’s stock, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00. Following the sale, the director now owns 130,944 shares in the company, valued at $7,131,210.24. This represents a 57.20 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 302,750 shares of company stock worth $16,139,410. 7.61% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SWTX shares. Guggenheim dropped their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Wedbush reiterated an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a report on Monday, February 10th. Finally, Evercore ISI upped their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $70.83.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.